Kelly Reveles, Pharm.D., Ph.D.

Kelly R. Reveles, PharmD, PhD, BCPS is an Assistant Professor with the Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin and an Adjoint Assistant Professor with the Pharmacotherapy Education and Research Center, School of Medicine, The University of Texas Health Science Center at San Antonio. She received her PharmD degree from UT Austin in 2010 and was recently the first graduate of the joint Translational Science PhD program offered by UT Austin, UT Health Science Center San Antonio, UT San Antonio, and UT School of Public Health. Her long-term research goal is to reduce the incidence and improve the outcomes of healthcare-associated infections by designing, testing, and implementing effective clinical strategies. Her current research focus is the prevention and treatment of Clostridium difficile infections and innovative methods to improve the translation of clinical research findings into practice.

Research Interests: 

Clostridium difficile infection, translational science, comparative-effectiveness research, patient-centered outcomes research, and pharmacoepidemiology

• Publications

  Reveles KR, Mortensen EM, Koeller JM, Lawson KA, Pugh MV, Rumbellow SA, Argamany JR, Frei CR. Derivation and validation of a Clostridium difficile infection recurrence prediction rule in a national cohort of veterans. Pharmacotherapy 2018 (Epub ahead of print).

  Reveles KR, Lawson KA, Mortensen EM, Pugh MV, Koeller JM, Argamany JR, Frei CR. National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. PLoS One 2017;12(12):e0189227.

  Reveles KR, Pugh MV, Lawson KA, Mortensen EM, Koeller JM, Argamany JR, Frei CR. Shift to community-onset Clostridium difficileinfection in the national Veterans Health Administration, 2003 to 2014. American Journal of Infection Control (Epub ahead of print).

  Reveles KR, Backo JL, Corvino FA, Zivkovic M, Broderick KC. Fidaxomicin versus vancomycin as first-line treatment for Clostridium difficile-associated diarrhea (CDAD) in specific patient populations: a pharmacoeconomic evaluation. Pharmacotherapy 2017;37(12):1489-1497.

  Reveles KR, Cosimi RA, Ryan CN, Chan LS, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut Oct 2017 (Epub ahead of print).

  Britt BS, Evoy KE, Lee GC, Reveles KR, Sorensen KM, Jones X, Bollinger M, Frei CR. Early use of ceftaroline fosamil use in the United States Veterans Health Care System. Drugs Aug 2017;77(12):1345-1351.

  Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes of among cancer patients diagnosed with Clostridium difficile infections in the United States community hospitals. BMC Infectious Diseases Jun 2017;17(1):448.

  Arizpe A, Reveles KR, Aitken SL. Regional variation in antibiotic prescribing among Medicare Part D enrollees, 2013. BMC Infectious Diseases Dec 2016;16(1):744.

  Pechal A, Lin K, Allen SM, Reveles KR. National age group trends in Clostridium difficile infection incidence and health outcomes in United States community hospitals. BMC Infectious Diseases Nov 2016;16(1):682.

  Reveles KR, Duhon BD, Moore RJ, Hand EO, Howell CK. Epidemiology of methicillin-resistant Staphylococcus aureus diabetic foot infections in a large academic hospital: implications for antimicrobial stewardship. PLoS One Aug 2016;11(8):e0161658.

  Argamany JR, Delgado A, Reveles KR. Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010. BMC Infectious Diseases Aug 2016;16(1):454.